FrancophonIA/ELRC3.0 huggingface dataset:
English: In the LEADER trial, the frequency of cholelithiasis and cholecystitis was 1.5% and 1.1% for liraglutide and 1.1% and 0.7% for placebo, respectively (see section 5.1).
Danish: I LEADER-studiet var hyppigheden af cholelithiasis og cholecystitis henholdsvis 1,5% og 1,1% for liraglutid og 1,1% og 0,7% for placebo (se pkt.
English: A single dose administration of lisinopril 20 mg with liraglutide resulted in a reduction of lisinopril AUC by 15%; Cmax decreased by 27%.
Danish: Administration af én dosis på 20 mg lisinopril sammen med liraglutid resulterede i en reduktion af AUC for lisinopril på 15%, og Cmax blev reduceret med 27%.
English: The most frequent adverse reactions leading to withdrawal for liraglutide-treated patients were nausea (2.8% of patients) and vomiting (1.5%).
Danish: De bivirkninger, der hyppigst førte til seponering for patienter behandlet med liraglutid, var kvalme (2,8% af patienterne) og opkastning (1,5%).
English: Based on adequate glycaemic control or tolerability, 30% of trial subjects remained on a dose of 0.6 mg, 17% escalated to a dose of 1.2 mg and 53% escalated to a dose of 1.8 mg.
Danish: Baseret på tilstrækkelig glykæmisk kontrol eller tolerabilitet forblev 30% af forsøgspersonerne på en dosis på 0,6 mg, 17% optrappede til en dosis på 1,2 mg og 53% optrappede til en dosis på 1,8 mg.
English: During use:
Danish: Efter ibrugtagning:
English: Be careful not to touch the display with your other fingers or press the dose selector sideways when you inject.
Danish: Undgå at røre ved dosisvinduet med fingrene eller trykke dosisvælgeren sidelæns under injektionen.
English: Atorvastatin Cmax was decreased by 38% and median tmax was delayed from 1 h to 3 h with liraglutide.
Danish: Atorvastatins Cmax blev reduceret med 38%, og medianværdien for tmax blev forsinket fra 1 time til 3 timer med liraglutid.
English: Mean weight change from baseline (kg)
Danish: Middel vægt ændring fra baseline (kg)
English: Animal studies have shown that the transfer of liraglutide and metabolites of close structural relationship into milk is low.
Danish: Dyreforsøg har påvist, at liraglutid og metabolitter, der er nært strukturelt beslægtede, kun i ringe omfang udskilles i modermælken.
English: There is no therapeutic experience in patients with end-stage renal disease, and Victoza is therefore not recommended for use in these patients (see sections 5.1 and 5.2).
Danish: Der er ingen klinisk erfaring hos patienter med nyresygdom i slutstadiet, og Victoza anbefales derfor ikke til disse patienter (se pkt.
English: Severe hypoglycaemia may occur uncommonly and has primarily been observed when liraglutide is combined with a sulfonylurea (0.02 events/patient year).
Danish: Alvorlig hypoglykæmi er ikke almindelig og er primært observeret, når liraglutid kombineres med sulfonylurinstof (0,02 hændelser/patientår).
English: When you are not using the pen, keep the pen cap on in order to protect from light.
Danish: Når du ikke bruger pennen, skal den opbevares med hætten påsat for at beskytte mod lys.
English: A single dose administration of digoxin 1 mg with liraglutide resulted in a reduction of digoxin AUC by 16%; Cmax decreased by 31%.
Danish: Administration af én dosis på 1 mg digoxin sammen med liraglutid resulterede i en reduktion af AUC for digoxin på 16%, og Cmax blev reduceret med 31%.
English: What you need to know before you use Victoza Do not use Victoza
Danish: Det skal du vide, før du begynder at bruge Victoza Brug ikke Victoza
English: The safety profile of liraglutide in combination with premix insulin was overall comparable to that observed for placebo in combination with premix insulin (see section 4.8).
Danish: Sikkerhedsprofilen for liraglutid i kombination med forblandet insulin var generelt sammenlignelig med den sikkerhedsprofil, der blev observeret for placebo i kombination med forblandet insulin (se pkt.
English: Mean baseline weight (kg)
Danish: Middel baseline vægt (kg)
English: Treatment with liraglutide in combination with metformin, metformin and glimepiride, metformin and rosiglitazone or SGLT2i with or without metformin was associated with a sustained weight reduction in the range from 0.86 kg to 2.62 kg compared with placebo.
Danish: Behandling med liraglutid i kombination med metformin, metformin og glimepirid, metformin og rosiglitazon eller SGLT2i med eller uden metformin var forbundet med en vedvarende vægtreduktion på mellem 0,86 kg og 2,62 kg sammenlignet med placebo.
English: Table 1 Adverse reactions from long-term controlled phase 3a trials, the long-term cardiovascular outcome trial (LEADER) and spontaneous (post-marketing) reports
Danish: Tabel 1 Bivirkninger i langvarige, kontrollerede fase 3a-forsøg, det langvarige kardiovaskulære endepunktsstudie (LEADER) og spontane (postmarketing) rapporteringer
English: No dose adjustment is required for patients with mild, moderate or severe renal impairment.
Danish: Dosisjustering er ikke nødvendig hos patienter med let, moderat eller svært nedsat nyrefunktion.
English: The small delay of gastric emptying with liraglutide may influence absorption of concomitantly administered oral medicinal products.
Danish: Den mindre forsinkelse af ventrikeltømningen, som liraglutid forårsager, kan påvirke absorptionen af samtidigt oralt indgivne lægemidler.
English: Few cases of acute pancreatitis (<0.2%) have been reported during long-term, controlled phase 3 clinical trials with Victoza.
Danish: Der er rapporteret om få tilfælde af akut pankreatitis (<0,2%) under de langvarige, kontrollerede kliniske fase 3-studier med Victoza.
English: Age had no clinically relevant effect on the pharmacokinetics of liraglutide based on the results from a pharmacokinetic study in healthy subjects and population pharmacokinetic data analysis of patients (18 to 80 years).
Danish: Alder havde ingen klinisk relevant effekt på farmakokinetikken af liraglutid baseret på resultaterne af et farmakokinetisk studie med raske forsøgspersoner samt en analyse af farmakokinetiske data for patientgrupperne (18 til 80 år).
English: Tap the cartridge gently with your finger a few times.
Danish: Bank forsigtigt på cylinderampullen et par gange med fingeren.
English: Patients treated with liraglutide had a significant decrease in body weight compared to that of patients treated with sitagliptin (-2.9 kg and -3.4 kg vs -1.0 kg, p<0.0001).
Danish: Patienter, behandlet med liraglutid, oplevede en signifikant reduktion i kropsvægt sammenlignet med patienter, behandlet med sitagliptin (-2,9 kg og -3,4 kg versus -1,0 kg, p<0,0001).
English: • Inflamed stomach (gastritis).
Danish: • Betændelse i maveslimhinden (gastritis).
English: Do not try to select other doses than 0.6 mg, 1.2 mg or 1.8 mg.
Danish: Forsøg ikke at vælge andre doser end 0,6 mg, 1,2 mg eller 1,8 mg.
English: In both groups a decrease in body weight was seen: -2.4 kg with liraglutide vs -1.09 kg with placebo.
Danish: Begge grupper oplevede en reduktion i kropsvægt: -2,4 kg med liraglutid versus -1,09 kg med placebo.
English: HR: 0.87 95% CI [0.78; 0.97]
Danish: HR: 0,87 95% CI [0,78; 0,97] p<0,001 for non-inferioritet p=0,005 for superioritet
English: Liraglutide in combination with metformin, glimepiride, metformin and rosiglitazone or SGLT2i ± metformin resulted in a statistically significant greater proportion of patients achieving an HbA1c ≤6.5% at 26 weeks compared with patients receiving these agents alone.
Danish: Liraglutid i kombination med metformin, glimepirid, metformin og rosiglitazon eller SGLT2i ± metformin resulterede i en statistisk signifikant større andel af patienter, der opnåede HbA1c ≤6,5% efter 26 uger, sammenlignet med patienter, som fik disse stoffer alene.
English: Estimated maximum liraglutide concentration was 9.4 nmol/l (mean body weight approximately 73 kg) for a subcutaneous single dose of liraglutide 0.6 mg. At 1.8 mg liraglutide, the average steady state concentration of liraglutide (AUCτ/24) reached approximately 34 nmol/l (mean body weight approximately 76 kg).
Danish: Den maksimale koncentration af liraglutid blev estimeret til 9,4 nmol/l (gennemsnitlig legemsvægt cirka 73 kg) for én subkutan dosis liraglutid på 0,6 mg. Med 1,8 mg liraglutid var den gennemsnitlige steady state-koncentration liraglutid (AUCτ/24) cirka 34 nmol/l (gennemsnitlig legemsvægt cirka 76 kg).
English: If you forget to use Victoza
Danish: Hvis du har glemt at bruge Victoza
English: Disodium phosphate dihydrate Propylene glycol Phenol
Danish: Dinatriumphosphatdihydrat Propylenglycol Phenol
English: Ethnic origin had no clinically relevant effect on the pharmacokinetics of liraglutide based on the results of population pharmacokinetic analysis which included patients of White, Black, Asian and Hispanic groups.
Danish: Etnisk oprindelse havde ingen klinisk relevant effekt på farmakokinetikken af liraglutid baseret på resultaterne af en analyse af farmakokinetiske data for patientgrupper med hvide, farvede, asiatiske og latinamerikanske patienter.
English: Favours Victoza Favours Placebo
Danish: Til fordel for Victoza Til fordel for placebo
English: Gastrointestinal adverse events were more frequently reported with liraglutide treatment (43.6% vs 37.1%).
Danish: Bivirkninger i mave-tarmkanalen blev rapporteret oftere ved behandling med liraglutid (43,6% versus 37,1%).
English: With each new pen, check the flow Check the flow before your first injection with each new pen.
Danish: Kontrollér gennemløbet af hver ny pen Inden din første injektion med en ny pen, skal du kontrollere gennemløbet.
English: Serious side effects
Danish: Alvorlige bivirkninger
English: Table 1 lists adverse reactions reported in long-term phase 3a controlled trials, the LEADER trial (a long-term cardiovascular outcome trial) and spontaneous (post-marketing) reports.
Danish: Tabel 1 viser bivirkninger, der blev rapporteret i langvarige kontrollerede fase 3a-forsøg, LEADERstudiet (et langvarigt kardiovaskulært endepunktsstudie) og fra spontane (postmarketing) rapporteringer.
English: Larger weight reduction was observed with increasing body mass index (BMI) at baseline.
Danish: Der blev observeret større vægtreduktioner for patienter med højere BMI ved baseline.
English: If you stop using Victoza
Danish: Hvis du holder op med at bruge Victoza
English: The use of Victoza is not recommended if you are on dialysis.
Danish: Victoza anbefales ikke, hvis du er i dialysebehandling.
English: Greater proportions of patients treated with liraglutide experienced transient nausea vs patients treated with sitagliptin (20.8% and 27.1% for liraglutide vs 4.6% for sitagliptin).
Danish: Et større antal patienter oplevede forbigående kvalme ved behandling med liraglutid sammenlignet med patienter behandlet med sitagliptin (20,8% og 27,1% for liraglutid versus 4,6% for sitagliptin).
English: Additional components in expanded MACE: Unstable angina pectoris (hospitalisation) Coronary revascularisation Heart failure (hospitalisation) Other secondary endpoints:
Danish: Ekstra kompenenter i udvidet MACE: Ustabil angina pectoris (indlæggelse) Koronar revaskularisering Hjertesvigt (indlæggelse) Andre sekundære endepunkter: Død uanset årsag
English: You may get hypoglycaemia (low blood sugar) when using Victoza together with a sulfonylurea or insulin, as sulfonylureas and insulin increase the risk of hypoglycaemia.
Danish: Dit blodsukker kan blive for lavt (hypoglykæmi), hvis du bruger Victoza sammen med sulfonylurinstof eller insulin, fordi sulfonylurinstoffer og insulin øger risikoen for hypoglykæmi.
English: At the beginning of the therapy, these gastrointestinal adverse reactions may occur more frequently.
Danish: Disse gastrointestinale bivirkninger kan forekomme hyppigere initialt i behandlingen.
English: Store away from the freezer compartment.
Danish: Opbevares på afstand af køleelementet.
English: >5.5 and <6.7 mmol/l (>100 and <120 mg/dl) 0-2 IUa ≥6.7 mmol/l (≥120 mg/dl)
Danish: >5,5 og <6,7 mmol/l (>100 og <120 mg/dl)
English: Post-hoc analysis of serious major adverse cardiovascular events (cardiovascular death, myocardial infarction, stroke) from all intermediate and long-term phase 2 and 3 trials (ranging from 26 and up to 100 weeks duration) including 5,607 patients (3,651 exposed to liraglutide), showed no increase in cardiovascular risk (incidence ratio of 0.75 (95% CI 0.35; 1.63)) for liraglutide versus all comparators.
Danish: Post hoc-analyse af alvorlige større kardiovaskulære hændelser (kardiovaskulær død, myokardieinfarkt, apopleksi) fra alle mellem- og længerevarende fase 2- og 3-studier (varende fra 26 til 100 uger), der inkluderede 5.607 patienter (3.651 eksponeret for liraglutid), viste ingen øget risiko for kardiovaskulære tilfælde (incidensratio på 0,75 (95% CI 0,35 til 1,63)) for liraglutid versus alle komparatorer.
English: When Victoza is added to a sulfonylurea or insulin, a reduction in the dose of sulfonylurea or insulin should be considered to reduce the risk of hypoglycaemia (see section 4.4).
Danish: Når Victoza anvendes som supplement til et sulfonylurinstof eller insulin, skal det overvejes at reducere dosis af sulfonylurinstof eller insulin for at mindske risikoen for hypoglykæmi (se pkt.
English: METHOD AND ROUTE OF ADMINISTRATION
Danish: ANVENDELSESMÅDE OG ADMINISTRATIONSVEJ
English: In the LEADER trial, severe hypoglycaemic episodes were reported at a lower rate with liraglutide vs placebo (1.0 vs 1.5 events per 100 patient years; estimated rate ratio 0.69 [0.51 to 0.93]) (see section 5.1).
Danish: I LEADER-studiet blev alvorlige hypoglykæmiske episoder indrapporteret mindre hyppigt med liraglutid versus placebo (1,0 versus 1,5 hændelser pr. 100 patientår; estimeret rate ratio 0,69 [0,51-0,93]) (se pkt.
English: Store in a refrigerator (2°C-8°C).
Danish: Opbevares i køleskab (2°C-8°C).
English: The need for treatment intensification with insulin was reduced by 48% with liraglutide vs placebo in insulin-naive patients at baseline (HR 0.52 [0.48;
Danish: Behovet for behandlingsintensivering med insulin blev reduceret med 48% med liraglutid i forhold til placebo hos patienter, som endnu ikke havde fået insulin, ved baseline (HR 0,52 [0,48; 0,57]).
English: Liraglutide exposure was reduced in patients with renal impairment compared to individuals with normal renal function.
Danish: Eksponeringen for liraglutid var reduceret hos patienter med nedsat nyrefunktion sammenlignet med forsøgspersoner med normal nyrefunktion.
English: If the dose selector stops before 0.6 mg lines up with the pointer, prepare a new pen and inject the full dose with the new pen.
Danish: Injicér den fulde dosis med en ny pen: Hvis dosisvælgeren stopper, før 0,6 mg er ud for markøren, skal du klargøre en ny pen og injicere den fulde dosis med den nye pen.
English: No data are available for children below 10 years of age (see sections 5.1 and 5.2).
Danish: Der er ingen tilgængelig data for børn under 10 år (se pkt.
English: The dose selector clicks when you turn it. Do not use these clicks to select your dose.
Danish: Brug ikke disse klik til at vælge din dosis.
English: Marketing Authorisation Holder and Manufacturer
Danish: Indehaver af markedsføringstilladelsen og fremstiller
English: - The other ingredients are disodium phosphate dihydrate, propylene glycol, phenol and water for injections.
Danish: - Øvrige indholdsstoffer: Dinatriumphosphatdihydrat, propylenglycol, phenol og vand til injektionsvæsker.
English: Patients receiving liraglutide in combination with a sulfonylurea or insulin may have an increased risk of hypoglycaemia (see section 4.8).
Danish: Patienter der får liraglutid i kombination med sulfonylurinstof eller insulin, kan have øget risiko for hypoglykæmi (se pkt.
English: At week 26, the estimated mean change in HbA1c was -1.4% and -0.5% for liraglutide and placebo, respectively, with an estimated treatment difference of -0.9 [-1.00; -0.70]95% CI.
Danish: I uge 26 var den estimerede middelændring i HbA1c -1,4% og -0,5% for henholdsvis liraglutid og placebo med en estimeret behandlingsforskel på -0,9 [-1,00; -0,70]95% CI.
English: • Proportion of patients achieving reductions in HbA1c Liraglutide alone resulted in a statistically significant greater proportion of patients achieving HbA1c ≤6.5% at 52 weeks compared with patients receiving glimepiride (37.6% for 1.8 mg and 28.0% for 1.2 mg vs 16.2% for comparator).
Danish: • Andel af patienter, der opnåede reduktioner af HbA1c Liraglutid alene resulterede i en statistisk signifikant større andel af patienter, der opnåede HbA1c ≤6,5% efter 52 ugers behandling sammenlignet med patienter som fik glimepirid (37,6% for 1,8 mg o 28,0% for 1,2 mg versus 16,2% for komparator).
English: Liraglutide stimulates insulin secretion in a glucosedependent manner.
Danish: Liraglutid stimulerer insulinsekretionen glucoseafhængigt.
English: Flatulence Abdominal distension Gastroesophageal reflux disease Abdominal discomfort Toothache
Danish: Opkastning Dyspepsi Smerter i øvre abdomen Konstipation Gastritis Flatulens Abdominal distension Gastroøsofageal reflukssygdom Abdominalt ubehag
English: - The active substance is liraglutide.
Danish: - Aktivt stof: Liraglutid.
English: Gender had no clinically meaningful effect on the pharmacokinetics of liraglutide based on the results of population pharmacokinetic data analysis of male and female patients and a pharmacokinetic study in healthy subjects.
Danish: Køn havde ingen klinisk betydende virkning på farmakokinetikken af liraglutid baseret på resultaterne af en analyse af farmakokinetiske data for mandlige og kvindelige patienter samt et farmakokinetisk studie med raske forsøgspersoner.
English: In patients treated with insulin prior to a confirmed hypoglycaemic episode the rate was higher with liraglutide (1.82 events/patient year) compared to placebo (0.91 events/patient years).
Danish: Hos patienter, der blev behandlet med insulin forinden en bekræftet hypoglykæmisk hændelse, var hyppigheden højere med liraglutid (1,82 hændelser/patientår) sammenlignet med placebo (0,91 hændelser/patientår).
English: MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS PRE-FILLED PEN LABEL
Danish: MINDSTEKRAV TIL MÆRKNING, DER SKAL ANFØRES PÅ SMÅ INDRE EMBALLAGER
English: Significantly more patients achieved HbA1c below 7% with liraglutide compared with exenatide (54.2% vs 43.4%, p=0.0015).
Danish: Signifikant flere patienter opnåede HbA1c under 7% med liraglutid sammenlignet med exenatid (54,2% versus 43,4%, p=0,0015).
English: No severe hypoglycaemic episodes occurred in the liraglutide treatment group.
Danish: Der forekom ingen alvorlige hypoglykæmiske hændelser i gruppen behandlet med liraglutid.
English: A significant and sustained reduction in HbA1c from baseline to month 36 was observed with liraglutide vs placebo, in addition to standard of care (-1.16% vs -0.77%; estimated treatment difference [ETD] -0.40% [-0.45; -0.34]).
Danish: En signifikant og vedvarende reduktion i HbA1c fra baseline til måned 36 blev observeret med liraglutid versus placebo givet som supplement til standardbehandlingen (-1,16% versus -0,77%; estimeret behandlingsforskel [ETD] -0,40% [-0,45; -0,34]).
English: The contraceptive effect is therefore anticipated to be unaffected when co-administered with liraglutide.
Danish: Det forventes derfor ikke, at kontraceptionsmidlernes virkning påvirkes ved samtidig administration med liraglutid.
English: Hypoglycaemia
Danish: Hypoglykæmi
English: Keep the pen cap on in order to protect from light.
Danish: Opbevar pennen med hætten påsat, for at beskytte mod lys.
English: Victoza 6 mg/ml injection Liraglutide
Danish: Victoza 6 mg/ml injektion Liraglutid
English: Guideline for titration of insulin glargine
Danish: Vejledning for titrering af insulin glargin
English: The pen is designed to be used with NovoFine or NovoTwist disposable needles.
Danish: Pennen er udviklet til brug med NovoFine- eller NovoTwist-engangsnåle.
English: Significantly more patients achieved HbA1c below 7% with liraglutide compared with placebo (52.8% vs 19.5%).
Danish: Signifikant flere patienter opnåede et HbA1c på under 7% med liraglutid sammenlignet med placebo (52,8% versus 19,5%).
English: Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Danish: Overfølsomhed over for det aktive stof eller over for et eller flere af hjælpestofferne angivet under pkt.
English: METHOD OF ADMINISTRATION
Danish: Administrationsmåde
English: After that, you may see a drop liraglutide at the needle tip.
Danish: Du vil muligvis se en dråbe liraglutid på nålens spids.
English: Disodium phosphate dihydrate, propylene glycol, phenol, water for injections
Danish: Dinatriumphosphatdihydrat, propylenglycol, phenol, vand til injektionsvæsker
English: Substances added to Victoza may cause degradation of liraglutide.
Danish: Lægemidler, der blandes med Victoza, kan medføre nedbrydning af liraglutid.
English: You can select doses of 0.6 mg, 1.2 mg and 1.8 mg.
Danish: Du kan vælge mellem doser på 0,6 mg, 1,2 mg og 1,8 mg.
English: The use of Victoza is not recommended if you have severe heart failure.
Danish: Victoza anbefales ikke, hvis du har alvorligt hjertesvigt.
English: No dose adjustment is recommended for patients with mild or moderate hepatic impairment.
Danish: Dosisjustering anbefales ikke for patienter med let eller moderat nedsat leverfunktion.
English: After first use: Store below 30°C or store in a refrigerator (2°C-8°C).
Danish: Efter ibrugtagning: Opbevares ved temperaturer under 30°C eller opbevares i køleskab (2°C-8°C).
English: Please tell your doctor, pharmacist or nurse if you are taking, have recently taken or might take any other medicines.
Danish: Fortæl det altid til lægen eller apotekspersonalet, hvis du bruger anden medicin eller har gjort det for nylig.
English: • A delay in the emptying of the stomach.
Danish: • En forsinkelse i mavetømningen.
English: Rate of confirmed hypoglycaemic episodes was higher with liraglutide (0.58 events/patient year) compared to placebo (0.29 events/patient year).
Danish: Hyppigheden af bekræftede hypoglykæmiske hændelser var højere med liraglutid (0,58 hændelser/patientår) sammenlignet med placebo (0,29 hændelser/patientår).
English: Then you can either:
Danish: Du kan nu gøre et af følgende:
English: Press the dose button to inject until 0 mg lines up with the pointer.
Danish: Tryk på dosisknappen til injektion, indtil der står 0 mg ud for markøren.
English: A drop of liraglutide should appear at the needle tip.
Danish: En dråbe liraglutid kommer til syne på nålens spids.
English: Increased heart rate
Danish: Øget hjertefrekvens
English: No episodes of severe hypoglycaemia were observed in the trial with liraglutide used as monotherapy.
Danish: Der blev ikke observeret episoder af alvorlig hypoglykæmi i forsøget med liraglutid som monoterapi.
English: For further instructions on administration, see section 6.6.
Danish: Yderligere anvisninger vedrørende administration findes i pkt.
English: NAME OF THE MEDICINAL PRODUCT AND ROUTE OF ADMINISTRATION
Danish: LÆGEMIDLETS NAVN, STYRKE OG/ELLER ADMINISTRATIONSVEJ(E)
English: Renal impairment Renal failure acute
Danish: Nedsat nyrefunktion Nyresvigt, akut
English: Pull off the inner needle cap and dispose of it.
Danish: Fjern den indre nålehætte og smid den væk.
English: Liraglutide in combination therapy, for 26 weeks, with metformin, glimepiride or metformin and rosiglitazone or SGLT2i ± metformin resulted in statistically significant and sustained reductions in HbA1c compared with patients receiving placebo (Table 2).
Danish: 26 ugers kombinationsterapi med liraglutid og metformin, glimepirid eller metformin og rosiglitazon eller SGLT2i ± metformin resulterede i statistisk signifikante og vedvarende reduktioner af HbA1c sammenlignet med patienter, der modtog placebo (Tabel 2).
English: Inject your dose
Danish: Injektion af dosis
English: Guide the needle tip into the outer needle cap without touching the needle or the outer needle cap.
Danish: Stik nålens spids ind i den ydre nålehætte uden at røre ved nålen eller nålehætten.
English: Liraglutide
Danish: Liraglutid
English: Add-on to SGLT2i5 ± metformin (≥1500 mg/day)
Danish: Tillægsbehandling til SGLT2i5 ± metformin (≥1.500 mg/dag)